Healthcare
MaxCyte, Inc.(MXCT)
Live Price
Offline$1.25
-1.57% today
1Y Change
-46.36%
Window
Jun 27, 2025 โ Jun 22, 2026
- Market Cap
- $90.00M
- Revenue Growth
- -14.5%
- EPS Growth
- -7.7%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 27, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MaxCyte, Inc. (MXCT) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $1.25 and down 46.4% across the available one-year price window (Jun 27, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -14.5%, EPS growth of -7.7%, a dividend yield of 0.0%. What stands out right now is revenue -14.5%, EPS -7.7%, free cash flow -23.6% with operating margin -131.9% and ROIC -23.0%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MXCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-14.5% vs +7.6% peer median
Operating Margin
Below sector median
-131.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -14.5% and EPS is at -7.7%, with operating margin around -131.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +6.9% | +4.9% | +7.8% |
2026 Mar 24, 2026 | +25.0% | -6.8% | -5.0% | +20.3% |
2025 Nov 12, 2025 | -9.1% | -4.4% | +7.6% | +1.3% |
Benchmark Edge
MXCT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MXCT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MXCT Max Drawdown
-70.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MXCT and SPY.
Company Overview
MaxCyte, Inc.
NASDAQ Global Select
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
- Leadership
- Maher Masoud
- IPO Date
- Jul 30, 2021
- Employees
- 114
- Street Address
- 9713 Key West Avenue
- Mailing
- Rockville, MD, 20850
- Region
- Rockville, MD, US
- Reporting Currency
- USD
- Investor Line
- 301 944 1700
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.8
- Price/Book
- 0.5
Growth
- Revenue
- -14.5%
- EPS
- -7.7%
- Free Cash Flow
- -23.6%
Profitability
- Gross Margin
- 68.4%
- Operating Margin
- -131.9%
- Net Margin
- -135.1%
- ROE
- -24.1%
- ROIC
- -23.0%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 8.30
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.